The cannabis industry today presents a blend of opportunity and risk—growth is fueled by ongoing state-level legalization, while federal uncertainty lingers in the background. Within this landscape, three companies stand out: Curaleaf Holdings (CURLF), Green Thumb Industries (GTBIF), and Innovative Industrial Properties (IIPR). Each brings a distinct approach—production, retail, and real estate—that makes them especially compelling investment opportunities.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Curaleaf (OTC:CURLF) | The Production Powerhouse
Curaleaf is a beast in cannabis production, operating in 17 states with 154 dispensaries and 19 cultivation sites. Their last report showed revenue of $314.5 million, a 1.5% increase sequentially from Q1 2025’s $310 million, though down 8% year-over-year from Q2 2024’s $342.3 million, reflecting U.S. market challenges like price compression. Net losses were $50.6 million, or $0.07 per share, slightly improved from Q1 2025’s $54.8 million but still pressured by domestic headwinds. Adjusted EBITDA was $65.5 million, maintaining a 21% margin, showcasing operational resilience despite a tough U.S. scene.
What’s driving excitement is Curaleaf’s international momentum, with international revenue hitting $41 million in Q2, up 62% year-over-year. The company now wholly owns Curaleaf International after buying out a minority partner, strengthening its European foothold, particularly with a new medical cannabis license in Turkey, set to launch in 2026. They have also lately focused on high-margin products like Select FormulaX. Both elements should help scale smartly, making them a strong producer pick with global ambitions.
Now, to be fair, the illicit market’s tax-free edge keeps margins tight, and Curaleaf’s $561 million debt load does raise eyebrows. But then again, their cultivation efficiency and new product launches, like the Anthem pre-rolls, signal a company leaning into growth markets like New Jersey and abroad, where legalization is gaining traction and catching up with the U.S. So if you’re betting on a producer with scale and international upside, I think Curaleaf’s got the roots to weather any storm.
Is CURLF Stock a Buy, Hold, or Sell?
Currently, analyst sentiment is fairly positive on Curaleaf. The stock carries a Moderate Buy consensus rating, based on two Buy and one Hold ratings assigned over the past three months. No analyst rates the stock a Sell. Meanwhile, CURLF’s average stock price target of $3.24 implies ~30% upside over the next twelve months.
Green Thumb (CNSX:GTII) | Retail’s Rising Star
Green Thumb is a play on the retail game, with the company running 105 stores across 14 states. In Q2, they generated $293.3 million in revenue, a 4.7% increase year-over-year, though slightly below the 11% growth previously reported. Despite a GAAP net loss of $0.65 million, primarily due to a one-time $11.7 million loss on the sale of assets, the company would have posted a net income of $11 million, or $0.05 per basic and diluted share, without this charge. This marks their 12th consecutive quarter of positive cash flow from operations, a rare feat in the cannabis industry.
But what really sets Green Thumb apart, in my view, is their licensing edge. These can be a goldmine for future growth since state regulators cap these tightly. Now, challenges loom, with Q2 EPS at -$0.01 (or $0.05 adjusted for a one-time $11.7 million loss on asset sales), down from the prior year’s $0.05 due to pricing pressures and expansion costs. Still, with $176.9 million in cash and $250 million in debt, they’re financially healthy for a retailer. Thus, I think Green Thumb’s mini-moat and profitability make it a beauty for investors eyeing consumer-facing cannabis plays.
Is Green Thumb Industries a Good Buy?
On Wall Street, Green Thumb stock features a Moderate Buy consensus rating based on two Buy ratings. No analyst rates the stock as a Hold or a Sell. GTBIF’s average stock price target of $13.90 implies about 84% upside potential over the next 12 months.
Innovative Industrial Properties (NYSE:IIPR) | The Real Estate Play with Staying Power
Innovative Industrial Properties (IIPR) flips the script as a cannabis-focused REIT, leasing properties to state-licensed operators, thus offering exposure to the space without touching the plant. Its last report showed total revenue of $62.9 million, down 21% from $79.8 million in Q2 2024, due to tenant defaults by operators like PharmaCann, 4Front Ventures, Gold Flora, and TILT Holdings.
Also, adjusted funds from operations (AFFO) were $48.4 million, or $1.71 per share, a 12% drop year-over-year, but it still topped analyst estimates of $1.61 per share. Despite the revenue hit, IIPR maintained its $1.90 quarterly dividend, now yielding a massive 14.6% showing confidence in its cash flow.
The defaults indeed sting, as top tenants like PharmaCann (11.5% of annualized base rent) and Green Thumb (7.7%) highlight concentration risk. But IIPR’s fighting back with a tenant refresh program, re-leasing a 205,000-square-foot Michigan property to Berry Green, and a $270 million investment in IQHQ, a life science REIT, to diversify beyond cannabis.
With $192 million in liquidity, a just 11% debt-to-gross-assets ratio, and a 15x debt service coverage ratio, IIPR’s balance sheet is a fortress ready to weather the storm. So, for investors wanting cannabis exposure with a safety net, I believe IIPR’s high yield and strategic pivot make it a solid pick, even with short-term bumps.
Is IIPR a Buy, Hold, or Sell?
Innovative Industrial Properties is currently covered by five Wall Street analysts, and sentiment is mixed. The stock carries a Hold consensus rating with one analyst currently bullish and one bearish. IIPR’s average price target of $67.50 indicates ~27% upside potential over the next twelve months, nonetheless.
Curaleaf, Green Thumb, and IIPR Set to Thrive in a Volatile Market
The cannabis sector continues to face challenges from pricing pressures, regulatory uncertainty, and illicit competition. Yet, Curaleaf, Green Thumb, and IIPR each offer investors distinct and compelling avenues of exposure. Curaleaf’s global expansion opportunity, Green Thumb’s profitability and licensing advantages, and IIPR’s high-yield real estate model showcase different strategies to capture industry growth. Risks remain, but these approaches provide both resilience and upside in an otherwise volatile market.